Source: National Ministry of Health (website)
Health department strengthens COVID-19 vaccination recommendations for girls, boys and teens | Published on Tuesday, October 17, 2023.
Given the increase in SARS-CoV-2 activity since the end of July, Argentina insists on the importance of vaccination as the most effective tool to maintain protection, focusing on high-risk groups.
(…) The goal of the national COVID-19 vaccination campaign is to reduce complications and deaths caused by the disease. In this sense, it is important that all persons over 6 months of age have a primary program with which reinforcement has been applied at least once in the past 6 months, and that they continue with the corresponding periodicity of reinforcement according to the following classifications:
High risk for severe COVID-19: People 50 years of age or older, pregnant women and people over 6 months old who are immunocompromised. Booster doses will be administered six (6) months after the last injection, and injections will continue at the same frequency (every 6 months).
Moderate risk for severe COVID-19 or high occupational exposure to SARS-CoV-2: People under 50 years of age with non-immunosuppressive comorbidities (chronic disease or obesity), health personnel and strategic personnel. A booster injection is given 6 months after the last injection and then annually.
Low risk of severe COVID-19: People aged between 6 months and 49 years (inclusive) without comorbidities. A booster injection is given twelve (12) months after the last injection and then annually.
The minimum interval between booster doses and between the main schedule and booster doses is four (4) months.
In this case, the focus is on starting or completing the primary vaccination schedule and receiving booster vaccinations.
The COVID-19 vaccine used in Argentina is safe and effective and can be administered on the same or different days as other vaccines on the calendar, with no minimum interval.
Visit the official news website: https://www.argentina.gob.ar/noticias/salud-refuerza-las-recomendaciones-de-vacunacion-contra-covid-19-para-ninas-ninos-y
Vizzotti and Filmus announce approval of vaccine against COVID-19 in Argentina | Published on Wednesday, October 18, 2023.
ANMAT approved the ARVAC Cecilia Grierson vaccine against COVID-19, developed entirely in Argentina, thanks to the coordination and joint work of public and private institutions, authorities reported. “This is a milestone for our country’s science,” they underlined. National Minister of Health Carla Vizzotti and Minister of Science, Technology and Innovation Daniel Filmus reported today that the National Agency for Medicines, Food and Medical Technologies (ANMAT) approved the registration in the medical profession Registered Argentine ARVAC Cecilia Grierson bivariable vaccine against COVID-19, jointly developed by CONICET, Universidad Nacional de San Martín (UNSAM) and the Laboratory of Pablo Cassará. This is a historical fact, as this is the first time a vaccine for an infectious disease has been designed and developed entirely in Argentina. (…)
Argentina’s first vaccine against COVID-19
The approval of the ARVAC Cecilia Grierson vaccine is the result of the coordinated efforts of more than 500 professional and technical personnel from different disciplines in 20 public and private institutions in the country. The vaccine can be stored at 2 to 8°C (refrigerator temperature) and can be used as an annual booster for individuals who have received other vaccine platforms such as adenovirus or RNA. The ARVAC vaccine, based on recombinant protein technology, is a safe technology that can be used in pregnant women, infants, immunosuppressed patients, and has been used for more than 20 years in neonatal hepatitis B vaccines or, more recently, in HPV vaccines. The platform can also easily adapt to the emergence of new variants in a relatively short period of three to four months. (…)
Visit the official website of the news: https://www.argentina.gob.ar/noticias/vizzotti-y-filmus-anunciaron-que-se-aprobo-la-vacuna-argentina-contra-covid-19
The Health Bureau introduces the progress of special drug library management | Published on Wednesday, October 18, 2023.
The presentation took place over the course of a day and was attended by different teams from across the country.
Relevant departments of the National Administration of Medicines and Health Technology met with the coordination representative of the National Specialty Drug Library and introduced the management progress in 2022-2023, including the procurement process, balances, and the situation in different jurisdictions. (…)
What is a Special Drug Library?
Special drug banks supplement jurisdictional/provincial coverage by supplementing jurisdictional access to drugs for patients with exclusive public insurance coverage primarily suffering from certain cancers, with the strict aim of equalizing health care standards and thus Achieve bigger goals. Equitable access to oncology medicines nationwide. Within this framework, special drug banks supplement the supply of drugs for more than 100 oncological diseases that are not available in the jurisdiction where the patient lives.
Visit the official website of the press: https://www.argentina.gob.ar/noticias/salud-presento-los-avances-de-la-gestion-del-banco-de-drogas-especiales